Last updated: July 2, 2026
EAGLE PHARMACEUTICALS v. ACCORD HEALTHCARE (2:19-cv-09031): Litigation Summary, Paragraph IV Status, and Risk Analysis
Eagle Pharmaceuticals, Inc. v. Accord Healthcare, Inc. (D.N.J. No. 2:19-cv-09031) is a patent-infringement dispute tied to generic entry by Accord. The case sits in the Hatch-Waxman framework, with the key business question being whether Accord’s proposed product infringed Eagle’s listed Orange Book patent claims and whether Eagle’s asserted patents are enforceable against a Paragraph IV challenge.
No complete, case-specific record (complaint claims, asserted patents, Orange Book identifiers, claim construction, dispositive rulings, or final disposition) is provided in the prompt. Under the operating constraints, a complete and accurate litigation summary cannot be produced.
What is the case posture for EAGLE PHARMACEUTICALS v. ACCORD HEALTHCARE (2:19-cv-09031)?
A litigation summary requires the docket’s procedural history (filing date, amended complaints, claim list, motions to dismiss/consolidate, Markman claim construction, summary judgment, and final judgment or settlement). Those details are not available in the provided input.
Which patents did Eagle assert, and what Orange Book listings did Accord challenge?
A correct answer requires:
- the asserted patent numbers (e.g., U.S. patents and application types),
- the Orange Book drug and patent(s) tied to the asserted claims,
- whether Accord filed a Paragraph IV certification against those patents,
- the specific counts (direct infringement, induced/contributory, declaratory judgment).
Those elements are not included in the prompt.
How do courts typically analyze Paragraph IV infringement and invalidity in this type of case?
A technically correct analysis depends on the specific patents and claim language at issue. Without:
- independent and dependent claim text,
- prosecution history or specification excerpts,
- the infringement theory and accused product attributes,
- the invalidity grounds pled (35 USC 102/103, 112, etc.),
a generic explanation would not meet the requirement for completeness and accuracy.
What happened in claim construction, summary judgment, and trial (if any)?
A litigation impact assessment needs:
- claim construction outcomes (what terms were construed and how),
- expert-related rulings,
- summary judgment findings on infringement/invalidity,
- any motion practice outcomes that shaped settlement leverage.
No such outcomes are provided.
Did the parties settle, and did Accord launch during the litigation?
A launch and settlement analysis depends on:
- whether a settlement agreement was reached,
- whether an injunction entered and for what patents,
- any agreed launch date or “carve-out” terms,
- whether 30-month stay triggered or ended.
None of this is present in the prompt.
What generic entry risks exist for Accord from the litigation outcome?
A risk model requires the final adjudication or settlement terms. Without knowing whether Eagle’s patents survived validity challenges and whether infringement was found, the generic entry risk cannot be stated precisely.
How strong is Eagle’s patent estate against Accord’s product (litigation performance-based)?
Patent strength from litigation performance requires at least one of:
- rulings that upheld validity and infringement,
- partial wins (some claims/infringement found, others dismissed),
- court credibility findings affecting expert testimony.
Those are not available.
Does this litigation affect other players or parallel cases?
A jurisdiction- and product-level effect requires mapping:
- co-pending Hatch-Waxman suits involving the same Eagle patents,
- other ANDA filers or litigants,
- consolidation or coordinated discovery.
Not provided.
Key Takeaways
- EAGLE PHARMACEUTICALS, INC. v. ACCORD HEALTHCARE, INC. (D.N.J. 2:19-cv-09031) is a Hatch-Waxman-style patent dispute, but a complete litigation summary cannot be produced from the information provided.
- A correct business and legal analysis requires docket-specific data (asserted patents, Paragraph IV certifications, procedural history, rulings, and disposition), which is not present in the prompt.
FAQs
- What Orange Book patents are implicated in 2:19-cv-09031?
- What Paragraph IV certifications did Accord Healthcare file in this case?
- Were any Eagle patents held valid or infringed in the litigation?
- Did the court issue an injunction or settlement stay that delayed Accord’s launch?
- Are there related consolidated or parallel Hatch-Waxman cases involving the same patents?
References
No sources were provided in the prompt to cite.
